



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Tuesday, November 24, 2009

FinnBrit Consulting

[View the current FinnBrit Consulting Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/35295-FinnBrit+Consulting.html)

(<http://www.bioportfolio.com/biocorporate/35295-FinnBrit+Consulting.html>)

Contact Details:

**Waltham
MA**

Tel: 781.894.2572

Fax:

Email: consulting@finnbrit.com

United States of America

Pharmaceutical products have complex and extended development cycles with an absolute minimum of at least five years for a new innovator product, and more than 3 years for a generic drug. Every extra day prior to launch costs money!

FinnBrit Consulting has the necessary experience to guide you through your drug development program beginning with preformulation and their subsequent process design, development and manufacturing to the eventual launch of the finished medicinal product.

Drug formulation has traditionally been considered the Cinderella of drug development. There are numerous pitfalls that must be avoided. The formulation must be stable, since a future stability problem results not only, in an additional cost for a new formulation, but also the cost of the delayed launch of the product.

Development projects have failed because of an inability to provide a stable, effective drug product.

An inadequate patent may result in a future loss of an infringement suit against a competitor. An inadequate understanding of the regulatory framework may lead to additional delays because of the need to answer supplementary questions from the regulatory agency and/or provide additional data.

In the same way that formulation is the Cinderella of drug development; excipients are the Cinderellas of formulation design. They do not treat any disease, but without them we cannot provide a formulation for any drug. Excipients are at the core of formulation design, and formulation scientists need to understand them very well. Poor understanding of the advantages and limitations of excipients can lead to poor formulations and costly delays.

In some cases you may be able to eventually save a failed project through additional costly trials or tests. However, the better the initial understanding of the integrated process of drug development, the less costly it will be.

FinnBrit Consulting provides timely advice on all aspects of drug development and excipients that reduce time lines and prevents pitfalls. Always remember that each extra day prior to launch costs money!

Press Releases on FinnBrit Consulting:

[Excellence in Healthcare Innovation Recognized by Frost & Sullivan](#)

23rd November, 2009 Frost & Sullivan

MOUNTAIN VIEW, Calif., Nov. 23 /PRNewswire/ -- Frost & Sullivan, the Growth Partnership Company, honored healthcare companies for demonstrating leadership and innovation Thursday, November 19,

[Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger](#)

23rd November, 2009 Anesiva, Inc.

SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Dr. Ted W. Love and Dr. David C. U'Prichard have agreed to join the Anesiva board

[Impax Laboratories Drives Stronger Performance with IBM Business Analytics](#)

20th November, 2009 IBM

-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether

[Spherix Announces the Closing of \\$6.3 Million Registered Direct Offering](#)

19th November, 2009 Spherix Incorporated

BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting

[Spherix Announces Results of Annual Shareholders Meeting](#)

19th November, 2009 Spherix Incorporated

-- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants

BioNews Results for FinnBrit Consulting



- [CuraBase to be Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference i](#)
PR-USA.net: Nov 15 2009 9:21AM Matching: consulting
- [CuraBase to be Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston](#)
NewsBlaze: Nov 14 2009 7:48PM Matching: consulting
- [CuraBase to be Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston](#)
PR.com: Nov 14 2009 7:47PM Matching: consulting

- [Tekmira Pharmaceuticals Corporation Announces Third Quarter 2009 Operating Results and Provides Corporate Upda](#)
Canadian Industrial Equipment News: Nov 14 2009 7:41PM Matching: consulting
- [Ondine Biopharma Announces Third Quarter 2009 Financial Results](#)
Canadian Industrial Equipment News: Nov 14 2009 7:41PM Matching: consulting
- [CuraBase to be Presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston](#)
NewsBlaze: Nov 14 2009 6:54PM Matching: consulting
- [One-day workshop on GCP in Hyderabad on Nov 30](#)
PharmaBiz: Nov 14 2009 3:33AM Matching: consulting
- [Open EC Technologies, WOW GLOBAL sign Teaming Agreement](#)
News-Medical.Net: Nov 13 2009 4:41AM Matching: consulting
- [Modular Planting Systems lend to buildings' sustainability](#)
ThomasNet: Nov 13 2009 2:25PM Matching: consulting
- [Suncor Energy Appoints New Members to Board of Directors](#)
Genetic Engineering News: Nov 13 2009 12:20AM Matching: consulting
- [Critical Outcome Technologies Inc. Engages Pullan Consulting to Obtain a Licencing Deal for COTI-2](#)
TradingMarkets: Nov 12 2009 5:40PM Matching: consulting
- [Critical Outcome Technologies Inc. Engages Pullan Consulting to Obtain a Licencing Deal for COTI-2](#)
Street Insider: Nov 12 2009 2:49PM Matching: consulting
- [Critical Outcome Technologies Inc. Engages Pullan Consulting to Obtain a Licencing Deal for COTI-2](#)
Reuters: Nov 12 2009 2:36PM Matching: consulting
- [Critical Outcome Technologies Inc. Engages Pullan Consulting to Obtain a Licencing Deal for COTI-2](#)
PR inside: Nov 12 2009 2:31PM Matching: consulting
- [Critical Outcome Technologies Inc. Engages Pullan Consulting to Obtain a Licencing Deal for COTI-2](#)
Yahoo! Canada: Nov 12 2009 2:28PM Matching: consulting

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

